A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Safety and Tolerability in Healthy Volunteers

Interventions

DRUG

SSS39

Single oral administration of SSS39

DRUG

SSS39

Single oral administration of SSS39

Trial Locations (1)

SSS39, Beijing

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY